CSL profit falls due to pandemic curbs

CSL says that its ability to collect plasma had been improving as social mobility increases. (AAP)

Biotech firm CSL has posted a $US1.76 billion ($2.46 billion) net profit in its half-year results, down 5 per cent, after the COVID-19 pandemic inhibited its ability to collect plasma, a core part of its business.

But the blood products giant was able to boost revenue through, in part, strong sales of seasonal flu vaccines in several continents.